Venture Connect is a live, in-person experience that is designed to maximize the visibility of growing companies and help entrepreneurs build relationships with people (investors, peers, customers, and/or partners) who can help them scale. This year’s summit will include sessions featuring emerging companies, networking and partnering opportunities, investor engagements, and more! Stay tuned for ways to help us design this event as we move into the new year.
Featured companies at Venture Connect will present on stage in front of investors, corporate partners, ecosystem resources, and potential talent.
WHO SHOULD APPLY?
Early-stage or scaling companies in the Technology, Food Innovation, Consumer Goods, and Life Science sectors.
Life Science Focus: Bio Pharma, Digital Health, Immunology, Medical Devices, Therapeutics, *and more!
Technology: Big Data, E-Commerce, Gaming, Marketing Tech, Robotics, *and more!
Food Innovation & Consumer Goods: Agtech, Cannabinoid, Health Consumer, Plant Science, Waste & Recycling, *and more!
*More focus areas are listed on the application.
Applications closed on January 17, 2022. Check back for announcements on featured companies!
Active Defender is a life-saving safety solution for schools. We empower forward thing administrators to arm staff with situational awareness tools where saving seconds can save lives. Active Defender puts an emergency campus map on your smartboard or in the palm of your hand because only make good decisions based on what they know and where they are. Safety is Priceless! It should also be much easier to achieve in times of a crisis.
Alacrity Medical Innovations
Alacrity Medical Innovations (AMI) seeks to transform the treatment of minor bleeding, initially for patients on anticoagulant medications (“blood thinners”) and ultimately for a broader population. We seek to develop novel, convenient devices for anti-coagulated patients to stop minor bleeding events at home. Alacrity Medical Innovations’ (AMI) first product is a patent-pending, novel, easy-to-use drug delivery device in combination with a unique indication for an anti-fibrinolytic (“blood clot stabilizer”). Our device will simultaneously absorb blood while delivering the anti-fibrinolytic directly to wounds to stop minor, life-interrupting bleeding in anti-coagulated patients.
Allstacks is a predictive forecasting and risk management platform that improves software development outcomes. By running machine learning and AI models across the data from the entire software development life cycle, Allstacks identifies at-risk initiatives then provides solutions to get them back on track.
Amalgent is a fixed-dose combination therapeutics company developing alternatives to traditional opioid pain medications based on FDA-approved drugs. The Company intends to develop three combination products – across both acute and chronic indications – to provide safe, effective pain relief to the $30B global opioid market.
Aperiomics’ mission is to advance healthcare and revolutionize microbial identification to improve human health. Aperiomics’ Xplore-PathoTM combines deep metagenomic sequencing and proprietary bioinformatic analysis to identify nearly 40,000 microorganisms in each sample (human, animal, plant). Our cutting-edge technology is delivered as a service and detects every known bacterium, virus, parasite, and fungus.
Aperiomics’ platform technology has broad application across diverse markets such as clinical, agriculture, environment, industry, and veterinary. The impact of Aperiomics’ technologies is substantial due to our unique approach to microbe detection – instead of blindly probing for a ‘needle in a haystack’, Aperiomics analyzes the entire ‘haystack’, harnessing the power of deep metagenomic sequencing and bioinformatics to identify everything in the haystack. Xplore-PathoTM is transformative, changing microbial identification forever.
APIE-Therapeutics is a preclinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients suffering from chronic disease associated with capillary vascular damage in endothelial & related tissues. Our therapeutic drug compounds targets the stimulation of the Apelin-APJ receptor to promote repair and regeneration in the endothelium organ vascular niche. Targeting the upstream of the disease pathophysiology is proposed as a best-in-class biology to halt/stop disease progression when compared to drugs targeting the downstream of the disease pathophysiology. The core technology was discovered at Research Triangle Institute (RTI) and advanced to APIE-T for late stage preclinical and clinical development.
The experienced Baebies team, after selling Advanced Liquid Logic to Illumina, has licensed back digital microfluidics to provide highly differentiated products to the newborn screening and pediatric testing markets. The first product, SEEKER, for high-throughput labs – is cleared by the FDA and is now available in both the US and abroad. The company’s second product, the FINDER point-of-care platform, just received its CE Mark and is pending FDA clearance. FINDER has also been repurposed for a SARS-CoV-2 molecular diagnostic test and will Emergency Use Authorization expected soon. The addressable markets are very large and the potential benefits even larger. The company is seeking capital to complement over $31 million in awarded NIH grants and has previously raised $39 million in equity . With two proprietary platforms, a growing installed base, and expanding diagnostic test menus the company is poised for rapid growth in
Battery Xchange(“BXE”) is a hardware B2BB2C company that supplies healthcare facilities with cutting edge environmental charging kiosks that provide portable batteries for their employees and visitors in a socially distant environment. BXE developed a rental platform & kiosks machine that allows healthcare professionals and visiting customers to rent portable batteries from them on-demand to take on-the-go. Hospitals can utilize BXE kiosks to promote, advertise, and/or showcase pertinent information to their employees, first responders, and patients.
CasTag is a revenue generating, research reagent company in Durham, NC that has developed a breakthrough CRISPR platform technology that enables high-throughput functional studies for drug discovery. Our mission is to offer products that tackle the major pain point scientists face in having high-quality tools for their gene-specific research and to reduce pre-clinical R&D timelines for critical and understudied diseases. CasTag will be the first company to generate a whole human genome CRISPR Knock-In arrayed library that can rapidly enable live imaging in a variety of disease models while offering unparalleled optionality in product formats given our platform. By investing in lab automation and leveraging our homology independent universal genome engineering (HiUGE) technology throughput, we will be able to offer over 120k catalog products by the end of 2021 that will revolutionize the protein analysis market. So far, CasTag research reagent products have been sold to both academic researchers and biopharma drug development teams. CasTag’s underlying HiUGE technology was published and featured as “Best of Neuron 2018-2019”, and we are actively shipping orders out of Biolabs North Carolina.
CathaidTM provides Healthcare a superior solution to the life-threatening problems associated with inadequate securement and maintenance of central line catheters. These problems (vascular complications, bloodstream infections) result in extended hospital stays and significant patient mortality.
Cell Microsystems is an early growth stage company that develops, manufactures, and markets innovative products for single cell biology with a focus on product applications. The CellRaft® AIR System, an automated platform to image, sort, and isolate single cells, has been purchased by leading academic, government, and pharma research organizations. The CytoSort Array is uniquely suited to both end-point destructive analysis of single cells for genomics as well as clonal propagation of single cells for CRISPR gene editing, stem cell research, and organoid development.
Cerebri AI is powering the personalized enterprise. We enable personalized commerce at the digital speeds required today. Our customer experience platform measures customers individually and recommends products and offers to drive engagement and revenue. We close the gap between enterprise data and execution with state-of-the-art technology driven by reinforcement learning and operations research under a UX made for business users.
Chekhub is a B2B SaaS business focused on the work order management software market. Founded in March 2020 with an experienced senior leadership team, Chekhub’s vision is to be the go-to app solution to help companies and field technicians get more done and maximize efficiency. Chekhub is solving a key customer problem of having a defined scope of work to be done and a platform to help identify and source more resources to get the work done. The product market fit has been established, with customers already on the platform either in beta or signed contracts. Chekhub has a clear focus, solving real customer problems, and built a solution that is getting customers attention.
Citranvi® Biosciences LLC is a pre-clinical stage company, incorporated in North Carolina (USA) in 2019 with a strong and seasoned leadership team having significant experience to advance vaccine technologies for clinical development and commercial licensure. Citranvi® has entered into a worldwide exclusive licensure agreement with Henry Jackson Foundation (HJF) for the advancement of Military Medicine (US Dept of Defense)to develop herpesvirus vaccine technology platforms towards commercial licensure, with particular focus on the development of two multi-antigen vaccines against infectious diseases caused by: (1) human cytomegalovirus (hCMV); and (2) Epstein-Barr virus (EBV). HJF has a strong intellectual property position on the vaccine candidates and composition with 21 patents filed world-wide (7 of which have been issued). Currently there are no vaccines licensed for the prevention of hCMV or EBV infections.
Clever Education Systems
Clever Education Solutions’ goal is to make available a Montessori-tailored solution that answers the multi-faceted needs of Montessori school constituencies, including administration, teaching staff, prospective and enrolled parents. It is a fully integrated, modular, cloud-based school management system, a Software as a Solution (SaaS) that is user-focused and easy to use.
CytoRecovery has developed a novel product system that enables the real time separation and recovery of live cell sub-populations from biological samples including tumor and frozen cell samples. The technology was invented by a team of scientists at Virginia Tech and exclusively licensed to Virginia Tech.
Drive Therapeutics is an early-stage drug development company developing dual-action oligonucleotide therapeutics for the treatment of ocular disorders Drives’s lead program combines two mechanisms of action to treat wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) , which will improve patient outcomes and reduce treatment burden.
Ecobot empowers the AEC and environmental consulting industry to better serve their clients by reducing the time and expenses required to complete environmental regulatory reporting. The field scientists in these industries make critical decisions that inform land use and Ecobot’s wetland management platform provides accuracy and efficiency for thousands of wetland delineation reports submitted to the USACE each month.
Ecree’s artificial intelligence (AI) technology provides immediate and unlimited guidance and feedback to students as they are writing. The interactions between students and the AI program address key foundational elements of writing for papers in different disciplines and occasions. A Humanities paper, an application for medical or law school, cover letters in a job application, or a personal statement for a fellowship or graduate school are just a few examples of writing that the Ecree program has helped students address. The AI program focuses on specific areas requiring attention. The result is a cost-effective way to address achievement gaps across student populations. Ecree has created original algorithms that use a rules-based approach to identify areas of strength and weakness. By using these accepted standards, Ecree is able to provide targeted feedback to students about their writing. In addition, this approach allows Ecree to provide teachers with precise diagnostic insights into student learning needs as students progress through their academic work. As a result, teachers can focus on specific areas of need when they work with students.
Embarc is an app that personalizes the running experience by generating training routes in a runner’s community mimicking the challenges of the course she’ll face on race day. You tell us what you’re preparing for, and we’ll build a personalized training plan focused on helping you conquer not just a distance, but your specific race course.
Equity Shift provides software that makes it easier for private companies to issue, sell, and transfer their securities.
Our patented automation unlocks the ability for most private entities to participate in secondary transfers, and easy-to-use tools assist with common activities like primary fundraising, convertibles, vesting, tender offers, and more.
Floodlight Software provides the industrial inspection market, containing more than 7200 service organizations worldwide, with a SaaS digital platform that manages their entire end-to-end inspection processes in a single place. Floodlight replaces all paper-based processes, excel usage, and one-off digital tools with an integrated system that is fully operational standalone, but can also link to companion enterprise applications. Floodlight utilizes a dynamic forms engine that makes it easy to support unique and differing reporting requirements from asset owners and operators, while still retaining a consistent and easy-to-use front-end interface for field inspectors. Floodlight incorporates costing and billing information, automatically calculates profitability, and builds information transparency that helps you more smartly and more effectively manage your operations. Floodlight lays the foundation for emerging technologies that further improve inspection operations and make industrial inspections safer for both inspectors and the general public: robots, drones and other un-manned vehicles; IIoT, sensors, continuous monitoring systems; data analytics and AI; AR/VR; etc. Floodlight Software provides efficiency
and process improvement today and sets the stage for long-term digital transformation.
Gemelli Biotech, the company behind ibs-smartTM and trio-smartTM, was founded by a team of physicians with a mission to advance the applications of microbiome research while putting the needs of patients first. Gemelli has partnered with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai to develop the findings of the latest microbiome-focused research into practical applications – like diagnostics and therapeutics – with ibs-smartTM and trio-smartTM being the first and foundational offerings.
GeneVentiv Therapeutics is developing the first effective gene therapy for Hemophilia A and Hemophilia B with or without inhibitors. Our therapy will be first to market for patients with inhibitors. Patients with inhibitors are unable to respond to current therapies and gene therapies in development due to neutralizing antibodies (inhibitors) formed by the body in response to treatment with missing clotting factor.
We are a free food delivery service that focuses on order aggregation in high density apartments, offices, and other multi-use spaces. By offering select delivery times/options we can deliver multiple orders at once which allows us to charge $0 to our customers and less of a % order fee to our partner restaurants.
Ideal Medical Technologies
Ideal Medical Technologies is developing an artificial pancreas for use in the hospital setting. Based on the results of our pre-clinical testing, in 2019 the FDA designated our FUSION artificial pancreas system a Breakthrough Medical Device. Our glucose control software is based on artificial intelligence, and was patterned on the bodies natural glucose control process (e.g., uses biomimicry). We should complete first in human testing of our device by Q1 2021. Since it has been shown that hyperglycemia increases the mortality rates of hospitalized COVID-19 patients by at least 100%, if we our able to demonstrate safe and effective glucose control in our original tests on diabetic patients in a clinical research center setting, and follow on studies on hospitalized COVID-19 patients, we plan on seeking an EUA for our device from the FDA by Q4. The indication for use would be glucose control on all hospitalized COVID-19 patients who are experiencing hyperglycemia – studies have shown that approximately 60% of hospitalized COVID-19 patients experience hyperglycemia. Our FUSION system should also improve the care of both ICU patients and diabetic patients in a non-ICU setting, as safe and effective glucose control in these patients has been shown to improve morbidity/mortality rates. These two groups of patients represent 14 million annual admissions to U.S. hospitals, and they consume approximately $400 billion in healthcare costs annually. Ideal Medical Technologies has been issued patents in both the U.S. and EU for its FUSION system.
IngateyGen is an agricultural biotechnology company whose mission is to deliver innovative peanut varieties with improved safety and nutritional value that offer enhanced health and wellness benefits for consumers by partnering with the food value chain to deliver quality products to market. We are passionate about solving the important and increasing problem of peanut allergy at its source. To that end, within our product pipeline, we are developing a commercially viable, allergen-free peanut from which all clinically relevant allergens have been eliminated. This will be achieved using agriculture’s newest gene editing breeding technologies, the most recent Nobel Prize winning gene editing technology, Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) or Transcription Activator-Like Effector Nuclease (TALEN). The resulting gene edited peanut variety is expected to be as nutritious and agronomically
equivalent to conventional peanuts.
InsightFinder is an AI-first system of intelligence that uses unsupervised machine learning to detect anomalies in machine data, predict incidents, and automate root cause analysis. Unlike alternatives, only InsightFinder follows the lifecycle of operational incidents providing the ability to detect, diagnose, remediate, and prevent outages.
The platform and patent portfolio are based on 15 years of research conducted by Dr. Gu, CTO, with support from IBM, Google, and the NSF. Organizations like China Mobile, Dell, and Credit Suisse use InsightFinder to automate systems management across logs, metrics, traces, and changes. Typical customers save $30,000 – $50,000 per month using InsightFinder to prevent service disruption
Instancy provides an “intelligent and integrated learning platform” that can compliment a client’s existing Learning Management legacy applications or provide an end-to-end learning system that automates and personalizes skills development and deliver the right knowledge to the right person at the right time.
Karios Technologies, Inc is a hydrogel medical device company that has developed a new technology capable of preventing post-surgical cardiac adhesions. This technology has been specifically designed for use on the heart to prevent cardiac adhesions. Cardiac adhesions result from the removal of the heart’s protective barrier during surgery. During healing, adhesions form and fuse the heart to neighboring tissues in the chest cavity increasing patient morbidity and mortality. Our mission is to protect the hearts of infants, children, and adults after heart surgery by preventing these adhesions. No adhesions prevention technologies are capable of preventing adhesions in cardiac situations. These cardiac adhesions increase the morbidity and mortality of the >500,000 infants, children, and adults per year in the US that have open-heart surgery. These cardiac adhesions also increase the surgery times and risks of reoperation of the >100,000 cardiac reoperations (>28,500 of which are infants and children) which occur annually. By preventing post-surgical cardiac adhesions, we will decrease patient morbidity and mortality for 100,000’s of patients in the US and eventually the world. We believe that success in the cardiac space, due to the unique challenges posed by application to the heart, will translate to a product capable of preventing adhesions in other surgical indications. Changing the paradigm of post-surgical adhesion prevention starts with the heart.
LabVoice is the first scientific voice platform that can be tailored to your lab, infrastructure (instruments & software), and existing processes. It leverages best-in-class natural language processing tools, our team’s many years of combined experience working with life sciences software, and an innovative approach to working with our customers to make the scientific voice assistant an integral part of labs across academia, life sciences, chemicals, food and beverage, and other lab-focused industries.
Lindy Biosciences is a development-stage company addressing formulation challenges in the rapidly growing biotherapeutics market. Our core technology, Microglassification, produces spherical, dense, stable particles of a therapeutic protein, ideal for solid injectable formulations such as high-concentration suspensions or encapsulation for controlled release. Over half of all antibody therapeutics are given intravenously, in part because the high dose required cannot be formulated as a solution in a volume small enough for subcutaneous injection. Lindy Biosciences is developing high-dose suspensions of protein that are suitable for subcutaneous injection, decreasing administration costs, increasing patient comfort and compliance, and enabling new high-dose molecules to reach the market.
Live.Give.Save. offers the first and only all-in-one mobile solution for giving and inspiring social good. Live.Give.Save’s product, Spave, enables consumers to aggregate and view all their bank accounts (across multiple banks), track and analyze spending, save for their future, pay down debt and reach charitable giving goals in one single app.
mesur.io is an emerging leader in the application of machine learning and advanced analytics to geospatial timeseries data. Our Earthstream platform automatically identifies, extracts, and links quantitative geospatial time series data with environmental and other relevant external data to provide predictions to end users regarding various risks. Our target markets are agriculture, food security/food supply chain, compliance, biological threats (COVID-19), and University researchers.
Metalytics provides critical information about cellular metabolic rates in living cells, giving our clients actionable results they can implement to accelerate research, development, and manufacturing timelines. Our technology-enabled and customized CoreMFA services allow investigators to quickly and rationally engineer improved cells and/or optimize cell culture media components with applications in a diversity of industries, including biopharma and specialty chemical manufacturing, biofuels production, synthetic biology, agricultural biotechnology, and cell-based food production. By highlighting the most promising engineering targets in metabolism, reduced time-to-market, increased production quantity and quality, lower capital requirements, and reduced raw material costs can be achieved.
MicroElastic Ultrasound Systems
MicroElastic is developing a handheld device that ultrasonically quantifies skin elasticity and thickness. This enables dermatologists to provide personalized care, and allows skincare manufacturers to prove their products really work. MicroElastic’s Bullseye device is currently being evaluated in clinical studies at Duke University as well as with several strategic partners. These partners represent future sales channels as well as potential exit opportunities. We are currently raising a Series Seed to achieve 510(K) clearance and launch our commercial product.
MycoMed improves the success of therapies used to treat cancer, organ failure, and autoimmune diseases by developing products that detect infections early, before progression of disease. Early detection enables personalized, pre-emptive therapies that decreases the burden of infection and improves survival.
Our woman-owned cleantech startup is developing innovative membrane filters to dramatically
reduce the cost of water purification using high-end desalination technology known as reverse
osmosis. Our membrane filters, based on our patent pending polymers, are built to operate within
existing reverse osmosis systems and demonstrate unique anti-fouling performance that keeps
systems running longer with less maintenance.
OncoTAb, Inc. is a biotechnology company founded with a mission to address unmet needs in breast cancer. The technologies developed to achieve this mission by the founders of OncoTAb are:
a. A patented monoclonal antibody (TAB004) that specifically recognizes the tumor form of MUC1 (tMUC1), a glycoprotein that has been prioritized as one of the most important cancer antigens by the National Cancer Institute (NCI).
b. A patent pending process to accurately detect biomarker levels in patients over time.
One Donation has leveraged technology (like GraphQL) to create an innovative way to support over 1.5 million nonprofits through payroll deduction. We harness the market forces of Corporate Social Responsibility and employee engagement to gain attraction and adoption. We sell through industry established channel partners and are built on a blockchain database.
OpiAID is a data science company creating innovative solutions for addiction treatment. Our software is designed to help medically-assisted treatment (MAT) clinics improve retention in their programs. When patients remain in treatment they have improved outcomes, the clinic’s revenue increases and payors save money.
We’re empowering hospital pharmacy leaders with the technology they need to proactively mitigate the ongoing impacts of medication supply chain disruptions. We achieve this through an intuitive data-unifying platform hospitals can quickly deploy to efficiently and effectively respond to supply chain threats, while protecting their patients from harm.
Pairwise is a mission-driven food+tech company dedicated to building a healthier world through better fruits and vegetables. Based in North Carolina’s Research Triangle, Pairwise is seeking to transform the $66B retail produce industry through the development of new varieties of differentiated produce. Pairwise holds licenses to base editing and high fidelity enzymes from Harvard and Massachusetts General Hospital, and our scientific founders Dr. Feng Zhang, Dr. David Liu, and Dr. J. Keith Joung, are eminent in the field of CRISPR and gene editing. Pairwise has build one of the best gene editing platforms in food and agriculture.
Panaceutics Nutrition (PN) delivers personalization, through the cost-effective manufacture of individualized nutrition products based on an individual’s genetics, stage of life, dietary habits, health conditions, and personal taste preferences. We bring together the expertise of a team of nutritionists, food scientists, biochemists, engineers, and management, drawing on the market experience of our partners to deliver products that are as unique as each one of us.
PBA is a drug discovery and development company using translational science and high- throughput biology to deliver better medicine for rare and orphan diseases. The company combines a primary cell biobank and organoid technology to create detailed, translational data sets that are mined for insight to inform key R&D decisions. PBA leverages its platform to accelerate target selection, to identify and characterize effective therapeutics, and to inform clinical strategy.
Peoplelogic is the first People Intelligence platform, improving performance, capacity, and accountability—cultivating a data-driven culture and decision making. It unlocks the insights hidden within your organization’s data fabric to empower leaders and managers to make better decisions, faster.
Founded in 2018 with technology developed at North Carolina State University, PhotoCide
Protection, Inc. is developing the SafeLight product line – a next-generation family of
environmentally-friendly products that can simultaneously disinfect a wide range of pathogens
(bacteria, fungi, and viruses), including drug-resistant strains, from surfaces.
PhotoniCare is building a low-cost diagnostic platform that uses light to see through tissue. The first product on this platform will fundamentally change the way physicians manage middle ear infections, the leading cause of hearing loss, antibiotic use, and surgeries in children, where the current gold standard is incorrect 50% of the time. With the TOMi Scope, physicians can now see through the eardrum to directly visualize the middle ear and determine whether antibiotic use or surgical intervention may be necessary. Diagnostic accuracy in a recent clinical study using the technology showed an accuracy of 90%+, suggesting significant improvement over the standard of care. PhotoniCare received FDA clearance for the TOMi Scope in early 2020 and is in early commercialization of the device.
Most people know that after a visit to a Physical Therapist, they will be provided a sheet of paper with exercises & stretches to do at home. To help those who need support in overcoming cognitive or motor function recover, Point Motion was founded: to provide remote patient monitoring tools for Health and Education specialists centered on music creation, allowing for client engagement interacting with music and empower healthcare specialists by collecting valuable data on their clients using accessible motion capture technology. This platform allows for patients to engage in interactive music-making experiences that collect vital data on their functional development over time objectively and automatically collecting data that is delivered directly to their healthcare/education specialist.
Praetego is an early stage biotech company with the goal to significantly improve the health and longevity of people living with diabetes. Our technology addresses an underlying cause of serious diabetic complications. Our primary indication is Diabetic Peripheral Neuropathy (DPN), a condition plaguing about 50% of diabetics. Our novel small molecules (Amadorins) are derived from a proven clinical prototype. The Amadorins are designed to limit disease progression. The candidates were developed in house and have earned two NIH/NIDDK grants to advance towards clinic. Praetego’s leadership and advisors have made substantial contributions to diabetes research and care.
RainBIO, Inc (RainBIO) is a spin-out of the University of North Carolina-Chapel Hill, and is based on the research of Dr. Brian Gilger, DVM, Professor of Ophthalmology at NCSU and Dr. Matt Hirsch, PhD, Associate Professor of Ophthalmology, Gene Therapy Center at UNC-Chapel Hill (UNC). Via a Carolina Express License from UNC-CH, RainBIO has exclusively licensed the Hirsch- Samulski technology to include the Company’s lead candidate, RBIO-1. RainBIO relies on a recombinant adeno-associated (rAAV) gene therapy strategy to prevent and reverse blinding disorders associated with lysosomal storage disorders (LSDs). The Company’s lead candidate (RBIO-1) is targeted to treat corneal clouding associated with Mucopolysaccharidosis type I (MPS I). RBIO-1 is a single stranded (ss) AAV8 gene therapy containing codon optimized human IDUA cDNA. RainBIO’s approach requires the administration to the corneal stroma of a very low rAAV dose of 1e9 viral genomes. The FDA granted RainBio’s RBIO-1 both Orphan Drug Designation (October 2020) and Rare Pediatric Disease Designation (September 2020). At least 5 other lysosomal storage disorders have been identified, all with similar ocular disorders, which represent additional indications that may also be addressed following the successful proof of concept of RBIO-1 in patients.
Revibe Technologies, Inc. creates wearable solutions to assist those who struggle with focus, attention and productivity. Their newest platform, Revibe Connect, was partially funded by the US Dept. of Education and is the company’s second successful product offering. This new device leverages researched-based vibration technology coupled with big data and machine learning to help promote focus and independence in children and adults with focus issues. Real-time user and clinical data is collected and shared through a mobile app with various stakeholders, such as teachers, parents, school systems and physicians to help drive improved outcomes and efficiencies through data.
SiNON Therapeutics patented Carbon NanoDots (CNDsTM) are a drug delivery system with a novel release mechanism that allows for targeted treatment for brain tumors and other neurological diseases. At SiNON Therapeutics we have developed a tunable, platform delivery system that is engineered to encapsulate multiple different therapeutics, including biologics, up to 500kD, and deliver them across the blood-brain barrier (BBB) to treat neurological diseases. Because our CNDs will open only at the site of the tumor and not at healthy tissues, we can deliver higher doses with less overall toxicity for increased therapeutic efficacy. It has been shown that 30-40% of cancers metastasize to the brain yet due to the fact that only 2% of therapies can cross the BBB, the survival rate for patients with brain cancers is only 34%. Our mission is to give hope to thousands of patients suffering from brain tumors that presently have few options for life-saving treatments.
SmartFox Technologies partnered with Salesforce, the leading CRM provider in the world, to build the first ever Business Forecast Management System application called SmartFox Prime©. SmartFox Prime is SaaS international award winning application available for purchase/download on Salesforce’s App Exchange for Salesforce Customers. SmartFox Prime helps companies save millions in miss forecast revenue by forcing Sales Teams to accurately forecast sales while eliminating poor opportunity management using technology called controlled artificial intelligence.
SoilMetrix provides exactly what farmers need and desire: a simple solution to a complex problem. SoilMetrix is the world’s first fully-automated, remotely sensed, software-as-a-service solution that optimizes crop yields and conserves nutrients, through adaptive means, allowing for the application of just the right amount of fertilizer to different parts of the same field. SoilMetrix creates geography-specific models of soil properties using remotely sensed, high resolution satellite imagery and topography together machine learning technology. The models allow us to predict a field’s soil property values at a high resolution and correlate them statistically to patterns of variability in light data, reflected by a field over time, that we discover using pattern recognition technology. We analyze the patterns and their soil models, and for each soil property, choose the set that makes the most beneficial agricultural impact. We deliver the patterns, called management zones, and their soil property values for each field as a digital soil map to farmers. Farmers can use the maps standalone or within their farm management software, for example to create variable rate prescriptions.
To meet the critical latency, performance and security requirements of 5G and Mobile Edge Computing applications a complete redesign of Kubernetes and infrastructure networking was needed. SunderIO (patent pending), is the Kubernetes-based Mobile Edge Computing platform from Sunder Networks.
We are an insuretech managing underwriter that underwrites property/casualty and workers compensation insurance on behalf of insurance companies. We leverage experienced personnel and a proprietary tech stack including an API engine, predictive tool, and underwriting algorithms to very quickly underwrite and administer small commercial policies. Our process takes a few minutes rather than a few days, which is usual and customary for the US insurance industry. Due to our structure and tech stack, we are intentionally designed to have far better scalability and more efficient cost structure than both insurance companies and managing general agencies.
Tellus Therapeutics is a neonatal care company whose mission is to develop safe and effective treatments for newborns in the neonatal intensive care unit (NICU). One in ten babies is born premature and at significant risk for white matter (myelin) injury and subsequent life-long cognitive and neurological impairments, such as cerebral palsy. There is no treatment for white matter injury which is the most common form of brain injury in babies born premature or full-term under hypoxic-ischemic conditions, e.g., sepsis, neonatal stroke and congenital heart disease. Tellus is developing novel small molecules derived from human maternal breast milk demonstrated to induce regeneration of myelin-producing oligodendrocytes and reverse white matter injury in an animal models of perinatal brain injury. Tellus is now pursuing a First-in-Neonate regulatory path to evaluate safety and efficacy in newborns with brain injury for whom no
treatments are available.
URO-1 develops solutions for office procedures in urogynecology and urology which drastically improve clinical outcomes and improve procedure efficiency. The company’s first product, the ReprisTM Bladder Injection System is market ready with FDA clearance, 4 issued patents, and validation of clinical, market, and manufacturing assumptions. An on-going pre-commercialization study indicates its use is associated with an order of magnitude improvement in clinical outcomes in the onabotulinumtoxinA (BOTOXTM) treatment of women with overactive bladder (OAB). The second product, the VMCoreTM Prostate Biopsy System, will increase the accuracy of prostate cancer diagnosis in addition to improving the workflow in the urology clinic and the pathology lab. The design of the tissue core collector is radically different from current
core collectors which have not changed in decades. A protocol for clinical procedures to validate design has been approved by an Institutional Review Board (IRB). A 510K application is under FDA review.
Vector Textiles(VT) is a North Carolina State Innovation “spin out” with three patents sub-licensed
from the University. VT makes a difference by dramatically lowering the risk of disease and death
from mosquitos, increasing crop yields and lowering water use for farmers, and making the
outdoors more accessible, all without the use of chemicals or pesticides.
We help parents know if their kids are struggling (or are on a path to struggling) with mental health issues and, if so, what to do about it. We analyze millions of data points from kids’ digital activities (text messages, social media, physical activity, etc.) using science, machine learning, and proprietary algorithms to find signals of mental health issues.
VitalFlo creates clinically validated tools, accessible to all, to proactively monitor chronic respiratory disease. We use the latest clinical research, behavioral science, and environmental science to empower patients to take charge of their health with a simple, intuitive experience. With our predictive analytics and data-driven insights, VitalFlo supports provider teams in making efficient, effective clinical decisions.
Without A Trace Foods
All the awesome. None of the compromise. Without A Trace Foods believes kids should not be defined by their allergies. We are a direct-to-consumer manufacturer and distributor of allergen-free snacks. As a busy family managing multiple food allergies, we understand the stressful, time consuming food dilemmas 85 million other Americans face daily. We help our customers simplify their snack shopping and bring peace of mind without all of the label reading. Our mission is to make all kids feel a part of things, never ostracized or othered because of food allergies. We want all of their friends to want to try their cool, colorful snacks. No more Snack 1 for kid A, Snack 2 for kid B and something different for the grown-ups. Our brand is designed with the whole family in mind.
At Zaloni, we believe in the unrealized power of data. Our DataOps software platform, Arena, streamlines data pipelines through an active catalog, automated control, and self-service consumption to reduce IT costs, accelerate analytics, and standardize security. We work with the world’s leading companies, delivering exceptional data governance built on an extensible, machine-learning platform that both improves and safeguards enterprises’ data assets